# OnCo record paper-traina-enzalutamide-ar-tnbc-jco-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-traina-enzalutamide-ar-tnbc-jco-2018" ;
  schema:name "Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer"@en ;
  schema:description "Enzalutamide gave clinical benefit at 16 weeks to a quarter of women with androgen receptor-expressing triple-negative breast cancer, a third among those with 10% or more staining, with fatigue the only common severe side effect."@en ;
  schema:url <https://onco.cc/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2016.71.3495>, <https://pubmed.ncbi.nlm.nih.gov/29373071/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2016.71.3495> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Traina TA, Miller K, Yardley DA, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/> ;
  onco:people <https://onco.cc/people/peter-schmid/>, <https://onco.cc/people/eric-winer/> ;
  onco:journals <https://onco.cc/journals/jco/> .